Shots:
Ocugen has licensed exclusive MENA rights for OCU400, its modifier gene therapy for retinitis pigmentosa, to Roots Pharmaceutical & its strategic partner Al-Dhow International Holding
As per the deal, Ocugen will receive ~$4M in upfront fee & development milestones, plus ~$255M in sales milestones, & royalties equaling 22% of OCU400 net sales by Roots…
